ALPHA — Pharnext SCA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development
Brief: Pharnext FY Operating Loss Widens To 27.8 Million Euros
Brief: Pharnext: Consolidation Of Shares Making Up Its Share Capital
Brief: Pharnext Halts Alzheimer's Disease Drug Candidate PXT864 Development
Brief: Neovacs: Commits To Project To Transform Pharnext's Legal Structure
Brief: Pharnext Says Is In Discussions With Edison To Update Its Research Note And Valuation Of Assets
Brief: Pharnext Gets Extra Funding From Neovacs, Appoints Hugo Brugiere As Chairman And CEO
Brief: Pharnext Announces Dr. David Horn Solomon Resignation From His Duties as CEO and Director, Appoints Joshua Schafer As Interim CEO and Dr. Jim Kuo As Director
Brief: Pharnext Completes Reverse Split Of Its Shares
Brief: Neovacs Sets Up Management Trust To Manage Pharnext Securities Issued, Rights And Obligations Of Neovacs
Brief: Pharnext H1 Operating Loss Widens To EUR 13.2 Mln
Brief: Pharnext: Financing Agreement With Néovacs For EUR 20.7 Mln Net To Further Develop PXT3003
Brief: Pharnext To Launch Reverse Stock Split
Brief: Pharnext Announces First Patient Enrolled In Open Label Extension Of Phase III Study Of PXT3003
Brief: Pharnext Announces EUR 2.5 Mln Loan Agreement With Neovacs
Pharnext shares gain a quarter on Phase III enrolment for CMT disease trial